|
|
CpG oligodeoxynucleotide 1826 |
|
Vaxjo ID |
221 |
|
Vaccine Adjuvant Name |
CpG oligodeoxynucleotide 1826 |
|
Adjuvant VO ID |
VO_0005579
|
|
Description |
A stable nanoparticulate DDA/MMG formulation that acts synergistically with CpG ODN 1826 to enhance the CD4鈦?T-cell response. It is described as a liposomal vaccine adjuvant. |
|
Stage of Development |
Research |
|
Structure |
The formulation is described as "nanoparticulate" and "liposomal". DDA is a quaternary ammonium compound and MMG is a monoglyceride. |
|
Appearance |
Nanoparticulate. |
|
Storage |
The formulation was optimized for stability, but specific storage conditions are not detailed. |
|
Preparation |
Formulations were investigated using dynamic light scattering and differential scanning calorimetry. Optimization was performed systematically using a design of experiment due to initial instability. |
|
Function |
Induces TFH responses in neonatal mice. It functions as an adjuvant that synergistically enhances CD4(+) T-cell responses. |
| References |
Karlsen et al., 2014: Karlsen K, Korsholm KS, Mortensen R, Ghiasi SM, Andersen P, Foged C, Christensen D. A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⺠T-cell response. Nanomedicine (London, England). 2014; 9(17); 2625-2638. [PubMed: 25529567].
Semmes et al., 2020: Semmes EC, Chen JL, Goswami R, Burt TD, Permar SR, Fouda GG. Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health. Frontiers in immunology. 2020; 11; 595297. [PubMed: 33552052].
|
|
